BioLineRx Ltd.

BioLineRx Ltd. is a drug development company that focuses on oncology. It was founded in 2003 and is headquartered in Modi'in, Israel. Its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. As of May 2023, its market cap is $46.9M.

BioLineRx's vision is to transform science into medicine by developing novel compounds that will deliver life-changing innovations for patients. It has a pipeline of powerful technologies that target different aspects of cancer, such as stem cell mobilization, immune cell infiltration, and patient-specific neoantigens.

One of its leading projects is **Motixafortide (BL-8040)**, a drug that blocks the interaction between CXCL12 and CXCR4, leading to robust mobilization of stem cells to the peripheral blood for collection and transplant, as well as increased immune cell infiltration into tumors and reduced immunosuppression in the tumor microenvironment. Motixafortide is currently in phase 3 clinical trials for stem cell mobilization and in phase 2 clinical trials for solid tumors.

BioLineRx has received several awards for its innovation and excellence, such as the Frost & Sullivan 2019 European Technology Innovation Award for AGI-134 and the Deloitte Israel Technology Fast 50 Award for being one of the fastest-growing technology companies in Israel.

Foundation: 2003
Headquarters: Modi'in, Israel
Website: https://www.biolinerx.com/